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Summary
Transforming growth factor-beta (TGF-β) suppresses T cell function to maintain self-tolerance and 
to promote tumor immune evasion. Yet how Smad4, a transcription factor component of TGF-β 
signaling, regulates T cell function remains unclear. Here we have demonstrated an essential role 
for Smad4 in promoting T cell function during autoimmunity and anti-tumor immunity. Smad4 
deletion rescued the lethal autoimmunity resulting from transforming growth factor-beta receptor 
(TGF-βR) deletion and compromised T-cell-mediated tumor rejection. While Smad4 was 
dispensable for T cell generation, homeostasis and effector function, it was essential for T cell 
proliferation following activation in vitro and in vivo. The transcription factor Myc was identified 
to mediate Smad4-controlled T cell proliferation. This study thus reveals a requirement of Smad4 
for T-cell-mediated autoimmunity and tumor rejection, which is beyond the current paradigm. It 
highlights a TGF-βR-independent role for Smad4 in promoting T cell function, autoimmunity and 
anti-tumor immunity.
Introduction
Transforming growth factor-beta (TGF-β) is important to maintain immune homeostasis and 
self-tolerance (Li et al., 2006b) and to promote tumorigenesis by inhibiting tumor immune 
surveillance (Wahl et al., 2006; Yang et al., 2010). Deletion of TGF-β1 leads to multifocal 
autoimmune disease (Shull et al., 1992), which underscores its essential role in suppressing 
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immune cell function. As a pleiotropic cytokine, TGF-β regulates various immune cell types 
including CD4+ and CD8+ T cells, natural killer cells, CD8αα+ T cells, B cells, and myeloid 
cells to control immunity (Cazac and Roes, 2000; Fridlender et al., 2009; Konkel et al., 
2011; Laouar et al., 2005; Li et al., 2006a; Liu et al., 2008; Marie et al., 2005; Yang et al., 
2008a). T cells are the critical target of TGF-β as disruption of TGF-β signaling specifically 
in T cells results in early lethal autoimmunity similar to what observed in germ-line TGF-
β1-deficienct mice (Li et al., 2006b; Liu et al., 2008; Marie et al., 2006). In addition, 
defective TGF-β signaling in T cells leads to enhanced tumor rejection (Gorelik and Flavell, 
2001). TGF-β controls T cell response through several mechanisms. It suppresses T cell 
proliferation and effector T cell function (Li et al., 2006b). In addition, TGF-β promotes the 
generation, maintenance and function of Foxp3-expressing regulatory T (Treg) cells that 
potently suppress immune response (Rubtsov and Rudensky, 2007). In the absence of TGF-β 
receptor (TGF-βR), T cells proliferate aberrantly in response to self-antigen (Zhang and 
Bevan, 2012). Such uncontrolled proliferation leads to uninhibited T helper-1 (Th1) cell-
associated responses. The overwhelming Th1 cell cytokine production impairs Treg cell 
function to further enhance inflammatory response, culminating into a systemic 
inflammation syndrome and lethal autoimmunity (Ishigame et al., 2013). Impaired TGF-β 
signaling contributes to inflammatory diseases and autoimmunity. Aberrantly enhanced 
TGF-β signaling in the tumor microenvironment thwarts immune surveillance and promotes 
cancer development. Therefore, in order to understand the etiology of autoimmunity and 
cancer and to devise effective therapies against these diseases, it is important to reveal how 
TGF-β functions in immune cells, especially in T cells.
TGF-β-activated pathways have been well-characterized in non-T cells (Shi and Massague, 
2003). TGF-β signaling is predominantly mediated by a Smad transcription factor-dependent 
pathway. Upon ligand binding, TGF-βR phosphorylates and activates receptor-associated 
Smad2 and Smad3, which subsequently associate with a co-Smad, Smad4, to control target 
gene expression (Attisano and Wrana, 2002; Massague, 1998). Mitogen activated protein 
kinases (MAPKs), including TGF-β-activated kinase 1 (TAK1), also mediate TGF-β 
signaling independent of Smad proteins (Derynck and Zhang, 2003). While the importance 
of TGF-β in controlling T cell function has been recognized for two decades, it is not until 
recent years that studies begin to delineate the contributions of Smad-dependent and –
independent pathways to T cell function. Conforming to the paradigm established in non-T 
cells, Smad2 and Smad3 are redundantly required for TGF-β suppressed T cell proliferation 
and Th cell differentiation, and for TGF-β promoted Treg cell generation (Gu et al., 2012; 
Takimoto et al., 2010). However TAK1 contributes to the homeostasis of thymic-derived 
Treg cells (Gu et al., 2012). Nevertheless, how Smad4 controls T cell function remains 
unclear.
Based on the current understanding of TGF-β signaling, one would predict that T cell 
specific deletion of Smad4, a co-Smad protein central for TGF-β signaling in non-T cells, 
would ablate TGF-β signaling in T cells and phenotypically resemble T cell specific TGF-
βR-deficient mice (Li et al., 2006b; Liu et al., 2008; Marie et al., 2006). Yet, mice with T 
cell specific deletion of Smad4 are grossly normal without apparent T cell activation (Yang 
et al., 2008b). In addition, when these mice are on a specific genetic background, they 
spontaneously develop cancer but not autoimmunity (Hahn et al., 2011; Kim et al., 2006). 
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Similarly, people with germ-line mutations of Smad4 predispose to familial juvenile 
polyposis and gastrointestinal cancers (Howe et al., 1998; Miyaki and Kuroki, 2003) but not 
autoimmune disease. These findings question the relationship between Smad4 and TGF-β 
signaling in T cells according to established notions. At least two possible explanations may 
account for these observations. One is that other co-regulator(s) for Smad2 and Smad3, such 
as TIF1γ (He et al., 2006), may compensate for the loss of Smad4 in T cells and that Smad4 
is dispensable for T cell function. The other is, while being involved in TGF-β-mediated 
suppression of T cell function, Smad4 also plays a critical role in promoting T cell function 
and the loss of Smad4 impairs T cell function to offset the effects of TGF-βR deficiency. 
Using genetic models, we provide evidence to support the latter explanation and reveal an 
essential role for Smad4 in T cell function during autoimmunity and tumor immunity.
Results
Smad4 deletion rescues lethal autoimmunity resulted from TGF-βR deficiency
To address whether Smad4 is dispensable for TGF-β signaling or has previously 
unappreciated function to counter-balance TGF-β-dependent function in T cells, we 
generated T cell specific Tgfbr2−/− Smad4−/− mice in which T cells were deficient in both 
TGF-βRII and Smad4 by crossing Cd4-cre mice(Lee et al., 2001) with Tgfbr2fl/fl and 
Smad4fl/fl mice (Chu et al., 2004; Chytil et al., 2002). If Smad4 is dispensable for T cell 
function, one would predict that T cell specific Tgfbr2−/− Smad4−/− mice develop early 
lethal autoimmunity as in Cd4-cre-Tgfbr2fl/fl mice (Li et al., 2006a; Marie et al., 2006). 
However, if Smad4 plays a role in counter-balancing TGF-β-dependent function, one will 
predict that Smad4 deletion would ameliorate the lethal autoimmunity in Cd4-cre-Tgfbr2fl/fl 
mice to display a phenotype similar to Cd4-cre-Smad4fl/fl mice. We found that, unlike Cd4-
cre-Tgfbr2fl/fl mice that succumbed to a systemic, lympho-proliferative, autoimmune 
syndrome by four weeks after birth, T cell specific Tgfbr2−/− Smad4−/− mice survived well 
beyond four months of age (Fig. 1a). While Cd4-cre-Tgfbr2fl/fl mice were runted, T cell 
specific Tgfbr2−/− Smad4−/− mice were similar in size as wild-type littermates (data not 
shown). Smad4 deletion in T cells therefore rescues early lethality of Cd4-cre-Tgfbr2fl/fl 
mice.
Abrogation of TGF-βR in T cells results in perturbed development of thymocytes (Li et al., 
2006a) and spontaneous activation of peripheral T cells (Li et al., 2006a; Marie et al., 2006). 
We assessed if deletion of Smad4 corrected these abnormalities. We first confirmed that 
Smad4 was efficiently deleted in Tgfbr2−/− Smad4−/− T cells and that the phosphorylation of 
Smad2, a hallmark for the activation of TGF-β signaling, was abrogated in these T cells 
(Supplemental Fig. 1a). The distribution of DN, DP, CD4+ SP, and CD8+ SP thymocyte 
populations appeared normal in T cell specific Tgfbr2−/− Smad4−/− mice (Supplemental Fig. 
1b). The expression of CD5, CD24 and CD69 was similar between Tgfbr2−/− Smad4−/− and 
wild-type thymocytes (Supplemental Fig. 1c). These findings suggest a normal thymocyte 
development in T cell specific Tgfbr2−/−Smad4−/− mice. In contrast to the increased 
lymphocyte numbers found in the periphery of Cd4-cre-Tgfbr2fl/fl mice, normal numbers of 
lymphocytes were recovered in T cell specific Tgfbr2−/−Smad4−/− mice (Fig. 1b). 
Importantly, while CD4+ and CD8+ T cells from Cd4-cre-Tgfbr2fl/fl mice were 
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spontaneously activated (Fig. 1c) and produced large amounts of interferon-γ (IFN-γ) (Fig. 
1d), T cells in T cell specific Tgfbr2−/−Smad4−/− mice maintained a naïve state (Fig. 1c) 
with minimal production of effector cytokine (Fig. 1d), similar to wild-type controls. Smad4 
is thus required for the spontaneous T cell activation due to defective TGF-β signaling in 
vivo.
Cell-intrinsic properties of Tgfbr2−/−Smad4−/− T cells are normal under steady state
Because T cell-extrinsic factors, such as the cytokine milieu and natural killer T (NKT) cell 
activation, may influence T cell phenotypes when TGF-β signal is disrupted (Li et al., 
2006a; Liu et al., 2008; Marie et al., 2006), we investigated if Tgfbr2−/−Smad4−/− T cells had 
cell-intrinsic defects not revealed in T cell specific Tgfbr2−/−Smad4−/− mice. We mixed 
equal numbers of bone marrow cells isolated from wild-type (CD45.1+) and T cell specific 
Tgfbr2−/−Smad4−/− (CD45.2+) mice and then transferred them into irradiated recipient mice 
deficient in recombination activated gene-1 (Rag1−/−). In the mixed bone marrow chimera, 
Tgfbr2−/−Smad4−/− thymocytes were generated to a similar extent as their wild-type 
counterparts (Fig. 2a) with normal expression of maturation markers (Supplemental Fig. 2). 
In addition, the percentages of CD62LloCD44hi effector T cells were comparable between 
wild-type and Tgfbr2−/−Smad4−/− T cells in the same hosts (Fig. 2b), suggesting that 
Tgfbr2−/−Smad4−/− T cells were not spontaneously activated in the chimeric mice. In 
agreement with this observation, the fractions of IFN-γ producing CD4+ Tgfbr2−/−Smad4−/− 
T cells were similar to that of wild-type counterparts. The fractions of IFN-γ producing 
CD8+ Tgfbr2−/−Smad4−/− T cells however were lower than that of wild-type cells (Fig. 2c). 
Therefore, while TGF-βR-deficient T cells are activated in vivo in a cell intrinsic fashion 
((Li et al., 2006a) and data not shown), Smad4 deletion corrects such a phenotype of these T 
cells.
Homeostasis of Tgfβr2−/−Smad4−/− Treg cells is defective
Impaired generation and function of Treg cells is one of the important mechanisms 
contributing to the lethal autoimmunity and spontaneous T cell activation in Cd4-cre-
Tgfbr2fl/fl mice (Li et al., 2006a; Marie et al., 2006). We investigated how Treg cells were 
affected in T cell specific Tgfbr2−/−Smad4−/− mice. Under steady state, similar frequencies 
and numbers of Foxp3+ Treg cells were found in T cell specific Tgfbr2−/−Smad4−/− and 
wild-type mice (Fig. 3a). In addition, the suppressive function of Tgfbr2−/−Smad4−/− Treg 
cells was comparable to wild-type Treg cells (Fig. 3b). Nonetheless, upon closer 
examination, we found that the cell intrinsic properties of Tgfbr2−/−Smad4−/− Treg cells 
were impaired. By creating and analyzing mixed bone marrow chimeric mice, we found 
that, although Tgfbr2−/−Smad4−/− Treg cells were much more efficiently generated than 
Tgfbr2−/− Treg cells in the chimeras (Fig. 3c), the percentage of Tgfbr2−/−Smad4−/− Treg 
cells was lower than that of wild-type counterparts in the same hosts (Fig. 3c). In addition, 
we investigated how Tgfbr2−/−Smad4−/− Treg cells were maintained under inflammatory 
conditions, because IFN-γ is important to disrupt the homeostasis of Treg cells in the 
absence of TGF-β signaling (Ishigame et al., 2013). The non-inflammatory environment in T 
cell specific Tgfbr2−/−Smad4−/− mice precluded us from addressing this question; we 
therefore created inflammatory conditions in vivo by using a T-cell-induced acute-graft 
versus-host disease (aGvHD) model. The same numbers of wild-type (CD45.1+) and 
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Tgfbr2−/−Smad4−/− (CD45.2+) T cells of C57BL/6 background were mixed at a ratio of 1 to 
1 and then transferred into irradiated IL2rg−/− mice of Balb/c background to induce strong 
inflammatory aGvHD response. Large amounts of IFN-γ were produced by T cells in the 
recipient mice (data now shown). Under such condition, the homeostasis of 
Tgfbr2−/−Smad4−/− Treg cells was greatly impaired when compared to co-existing wild-type 
Treg cells (Fig. 3d). Collectively, these observations suggest that deletion of Smad4 is not 
able to restore normal Treg cell homeostasis in the absence of TGF-βR.
The proliferation of Tgfbr2−/−Smad4−/− T cells is impaired
The findings described above prompted us to investigate whether the function of 
Tgfbr2−/−Smad4−/− non-Treg cells was impaired. In the absence of TGF-βR, aberrant T cell 
proliferation in response to self-antigen and overly exuberant Th1 cell differentiation lead to 
lethal autoimmunity in mice (Ishigame et al., 2013; Li et al., 2006b; Marie et al., 2006; 
Zhang and Bevan, 2012). Therefore, aberrant T cell activation, proliferation and Th cell 
differentiation are the key elements for uncontrolled T cell function in the absence of TGF-β 
signal. Tgfbr2−/−Smad4−/− T cells may be defective in these processes. Upon T cell receptor 
(TCR) ligation, Tgfbr2−/−Smad4−/− T cells up-regulated the activation markers similarly to 
wild-type cells (Supplemental Fig. 3a). Nonetheless, fewer numbers of Tgfbr2−/−Smad4−/− T 
cells were recovered compared to that of wild-type T cells three days after TCR ligation 
(Supplemental Fig. 3b). Such a reduction was likely due to impaired proliferation of 
Tgfbr2−/−Smad4−/− T cells (Fig. 4a), as these T cells survived similarly as wild-type T cells 
(Supplemental Fig. 3c) with comparable expression of the genes controlling cell survival 
(Supplemental 3d). In addition, the cell sizes of Tgfbr2−/−Smad4−/− T cells measured by 
forward-scatter by flow-cytometry were smaller than that of wild-type T cells after being 
activated in vitro (Fig. 4b), suggesting a defect in the growth of such T cells. The defective 
expansion of Tgfbr2−/−Smad4−/− T cell population could also be observed during a GvHD 
response in vivo (Fig. 4c), an allo-immune response that shares many features with 
autoimmune response (Shlomchik, 2007; Welniak et al., 2007). While Tgfbr2−/−Smad4−/− T 
cells could be differentiated into Th1 and Th2 cells similarly to wild-type T cells (Fig. 4d 
and Supplemental Fig. 3e), they failed to differentiate into Foxp3+ Treg cells in the presence 
of TGF-β (Chen et al., 2003) (Fig. 4d). Lack of TGF-β-induced Treg cell differentiation 
agreed with and contributed to the observation that fewer Tgfbr2−/−Smad4−/− than wild-type 
Treg cells were recovered in mixed bone marrow chimeras and during GvHD response (Fig. 
3c and 3d). Therefore, Tgfbr2−/−Smad4−/− T cells are defective in activation-induced 
proliferation.
Smad4 is required for T cell function in inflammation and cancer
Aforementioned observations suggest that Smad4 plays an essential role in promoting T cell 
function. To test this possibility, we investigated whether the activation, proliferation and/or 
differentiation of T cells were affected in the absence of Smad4. Naïve T cells isolated from 
Cd4-cre-Smad4fl/fl mice were activated normally with efficient up-regulation of activation 
markers (Supplemental Fig. 4a). Fewer Smad4-deficient than -sufficient T cells were 
recovered three days post activation (Supplemental Fig. 4b). While Smad4-deficient T cells 
survived similarly as wild-type T cells (Supplemental Fig. 4c) with comparable expression 
of genes that control T cell survival (Supplemental Fig. 4d), the proliferation of Smad4-
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deficient T cells was impaired following TCR stimulation in vitro (Fig. 5a). In addition, the 
sizes of activated Smad4-deficient T cells were smaller than that of Smad4-sufficient T cells 
in vitro (Fig. 5b) indicating that activation induced growth of Smad4-deficient T cells was 
impaired. While Th1 and Th2 cell differentiation and IL2 production of Smad4-deficient 
CD4+ T cells were largely normal (Supplemental Fig. 4e, 4f, and 4g), TGF-β-induced Treg 
cell differentiation of these cells was defective (Supplemental Fig. 4e), which is in 
agreement with a previous report (Yang et al., 2008b) and suggests that Smad4 indeed 
mediates TGF-β signaling in T cells.
Similar to Tgfbr2−/−Smad4−/− T cells, Smad4−/− T cells expanded poorly when compared to 
wild-type cells during a GvHD response in vivo (Fig. 5c). This observation could be due to 
impaired proliferation driven by lymphopenic condition and/or by cognate antigen 
stimulation. Smad4-deficient T cells proliferated less than wild-type T cells when 
transferred into sub-lethally irradiated syngeneic recipients, (Fig. 5d), suggesting Smad4 is 
required for lymphopenia-driven T cell proliferation. To test how Smad4 deletion may affect 
T cell proliferation in response to cognate antigen, we crossed Cd4-cre-Smad4fl/fl mice with 
OTII TCR transgenic mice to obtain Cd4-cre-Smad4fl/fl-OTII T cells that respond 
specifically to peptide 323–339 of chicken ovalbumin protein (OVA). Compared to co-
transferred wild-type OTII cells, Smad4-deficient OTII cells proliferated less in response to 
OVA protein stimulation in the immune competent syngeneic hosts (Fig. 5e and 
Supplemental Fig. 4h).
Smad4 mutation has been associated with cancers in human and mice (Hahn et al., 2011; 
Howe et al., 1998; Kim et al., 2006; Miyaki and Kuroki, 2003). The immune etiology is not 
entirely clear, although enhanced Th cell responses may contribute to cancer development 
(Hahn et al., 2011; Kim et al., 2006). The finding that Smad4-deficient T cells proliferated 
poorly to cognate antigen stimulation suggests Smad4 may be required for T cell mediated 
tumor rejection. Indeed, while the growth of engrafted OVA-expressing B16 melanoma was 
controlled effectively in wild-type OTII TCR transgenic (Tg) recipient mice, a large 
percentage of Cd4-cre-Smad4fl/fl-OTII mice developed melanoma after tumor cell 
engraftment (Fig. 5f).
The above mentioned observations suggest that, although Smad4 is largely dispensable for T 
cell activation and Th cell differentiation, it is required for T cell proliferation in response to 
cognate-antigen to promote T cell mediated inflammatory disease and tumor rejection.
Myc transcription factor is important for Smad4-controlled T cell proliferation
We further investigated the molecular mechanisms underlying the defective growth and 
proliferation of activated Smad4-deficient T cells. Because Myc is a central regulator for T 
cell growth and proliferation (Nie et al., 2012; Wang et al., 2011) and Smad4 has been 
suggested to promote Myc expression in tumor cells (Lim and Hoffmann, 2006), we 
hypothesized that the expression of Myc was dysregulated in Smad4-deficient T cells. 
Indeed, following activation, Myc expression in Tgfbr2−/−Smad4−/− and Smad4−/− T cells 
was lower than in wild-type T cells (Fig. 6a and 6b), suggesting that Myc functions 
downstream of Smad4 to control T cell proliferation. To test whether Myc downregulation is 
functionally important for defective proliferation of Smad4-defiicent T cells, we expressed 
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Myc in activated Smad4-deficient T cells using retrovirus-mediated gene delivery. Ectopic 
Myc expression largely restored the proliferation of Smad4-deficient T cells after activation 
in vitro (Fig. 6c) as well as in vivo during a GvHD response (Fig. 6d and Supplemental Fig. 
5), indicating that Myc is an important Smad4 downstream target to control T cell 
proliferation, whereas Myc-independent mechanisms might also be involved. Smad4 may 
promote Myc expression by binding to a TGF-β independent site in the Myc locus in T cells 
(Lim and Hoffmann, 2006). Using chromatin-immuno-precipitation (ChIP) assay, we found 
that Smad4 binding was enriched at this site in T cells (Fig. 6e). Therefore, one of the 
important mechanisms by which Smad4 promotes T cell proliferation is through regulating 
Myc expression.
Discussion
TGF-β suppresses autoimmunity and promotes tumorigenesis by regulating T cell function. 
Nonetheless, how Smad4 (a central component for TGF-β signaling) is involved in T cell 
function during autoimmunity and malignancies is unclear. T cell specific deletion of Smad4 
is associated with cancer but not with autoimmunity (Hahn et al., 2011; Kim et al., 2006). 
Here, we found that Smad4 was essential for the proliferation of T cells and Myc expression. 
Importantly, deletion of Smad4 in T cells rescued early lethal autoimmunity in mice whose 
T cells lack TGF-βR and led to impaired tumor rejection. These findings therefore reveal a 
previously unappreciated requirement of Smad4 to promote T cell function for 
autoimmunity and tumor immune surveillance. The information gained from this study 
sheds light on TGF-β signaling and Smad function, and provides insights into the control of 
T cell function, autoimmunity and cancer.
Aberrant T cell proliferation, uncontrolled T cell activation and effector function contribute 
to various types of inflammatory diseases. Therefore, inhibiting the proliferation and pro-
inflammatory function of T cells is effective to treat such illness. Current strategies aiming 
to interfere with pro-inflammatory T cell function often lead to the ablation of lymphocyte 
population and abrogation of effector T cell function, which could be detrimental to the 
patients. It is therefore important to identify pathways that are essential for autoimmunity 
development but largely dispensable for T cell homeostasis. By studying Cd4-cre-Tgfbr2fl/fl 
mice whose T cells lack TGF-β signaling, a pathway frequently impaired in various 
autoimmune and inflammatory diseases (Li et al., 2006b), we found that Smad4 deletion 
corrected the lethal autoimmunity in these mice. While Smad4-deficient T cells were 
generated, maintained, activated and differentiated normally, their proliferation was 
impaired. Therefore, one of the key steps leading to autoimmunity in mice lacking TGF-β 
signaling is the aberrant T cell proliferation, which is a prerequisite for the uncontrolled T 
cell activation and differentiation in these mice as suggested by a previous study (Zhang and 
Bevan, 2012). More importantly, this observation suggests that modestly inhibiting T cell 
proliferation could be sufficient to prevent autoimmunity and that Smad4 may be a 
promising target for treating autoimmunity without the drastic measures of ablating T cell 
population or function.
Treg cells are critical to maintain self-tolerance and immune homeostasis. Impaired Treg 
cell function has been implicated in nearly every autoimmune and inflammatory disease. It 
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is therefore thought that defective Treg cell function will invariantly lead to inflammatory 
disorders. We found that, although Smad4 deletion rescued the early lethal autoimmune 
syndrome and restored naive T cell phenotype in mice whose T cells lacking TGF-βR, the 
homeostasis of Tgfbr2−/−Smad4−/− Treg cells was defective especially under inflammatory 
conditions. These findings indicate that impaired Treg cell function may not always lead to 
inflammation and autoimmunity when the function of conventional T cells is defective albeit 
to a modest extent.
This study sheds light on the etiology of certain cancers. People with loss function mutation 
of Smad4 are predisposed to the development of familial juvenile polyposis and gastric-
intestinal cancers at older age (Howe et al., 1998; Miyaki and Kuroki, 2003). The immune 
etiology of such cancers is not entirely clear. While increased Th cell differentiation of 
Smad4-deficient T cells is associated with cancer development (Hahn et al., 2011; Kim et 
al., 2006), other mechanisms may also contribute. The current study provides another 
plausible immune mechanism for the cancer development in people with Smad4 mutation. 
We found that Smad4-deficient cells proliferated poorly in response to cognate and tumor 
antigen and showed reduced ability to reject engraft tumor cells. Therefore, Smad4 mutation 
impairs T cell mediated tumor rejection to allow tumor growth. These new insights may 
facilitate the development of effective anti-cancer drug. Blocking TGF-β signaling has been 
explored as an immunotherapy against cancers (Bierie and Moses, 2006; Yingling et al., 
2004). The observation that Smad4-deficient T cells are functionally defective even when 
TGF-β signaling is abrogated suggests that anti-TGF-β signaling immunotherapy may be 
tumor type specific and may not be efficacious when Smad4 function is perturbed.
We found that Smad4-deficient T cells proliferated poorly compared to wild-type T cells 
even in the absence of TGF-β signaling. It suggests that the proliferation of T cells is 
controlled by Smad4-dependent, TGF-β-independent pathways. Smad4 is a hub integrating 
multiple signaling pathways. Smad4 mediates the signaling of TGF-β superfamily members 
including TGF-βs, bone morphogenetic proteins (BMPs), activins and growth differentiation 
factors (GDFs) (Massague et al., 2005). In addition, Smad4 is involved in Wnt and Notch 
signaling (Massague, 2012). Moreover, Smad4 interacts with critical cell cycle regulators, 
such as E2Fs, that do not mediate specific upstream signaling (Taylor and Wrana, 2008). 
Therefore, Smad4 may control T cell proliferation through many diverse pathways 
independent of TGF-β. BMP signaling may be involved in this process as it has been 
suggested that BMP signaling is important for T cell proliferation (Yoshioka et al., 2012). 
We found that Smad4 is required for optimal Myc expression in T cells. Previous studies 
show that, through a TGF-β-independent mechanism, Smad4 promotes Myc expression in 
tumor cells by cooperating with TCF1 (Lim and Hoffmann, 2006), a factor important to 
mediate Notch and Wnt signal in T cells (Staal et al., 2008; Weber et al., 2011). Because 
Notch and Wnt signal promotes cell proliferation (Artavanis-Tsakonas et al., 1999; Staal et 
al., 2008), Smad4 may control T cell proliferation also through Notch and Wnt-TCF1 signal 
axis. Therefore, Smad4 may promote T cell function by integrating multiple pathways 
independent of TGF-β. The question of what the Smad4-dependent pathways are and how 
precisely they contribute to T cell function through Smad4 in vitro and in vivo is of interest 
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and warrants further investigation in order to understand the etiology of and devise therapies 
against diseases including autoimmunity and cancer.
Experimental Procedures
Mice
Smad4fl/fl, Tgfbr2fl/fl, Cd4-cre, Rag1−/−, OTII and CD45.1 congenic wild-type mice were on 
the C57BL/6 background. Rag2−/−Il2rg−/− mice were on the BALB/c background. All mice 
were housed and bred in specific pathogen–free conditions in the animal facility at the 
University of North Carolina at Chapel Hill. All mouse experiments were approved by 
Institution Animal Care and Use Committee of the University of North Carolina.
Flow-cytometry and cell sorting
Lymphocytes were isolated from the various organs of age- and sex-matched mice 3–16 
weeks of age. Fluorescence-conjugated anti-CD4 (GK1.5), anti-CD8 (53–6.7), anti-CD5 
(53–7.3), anti-CD24 (30-F1), anti-CD25 (PC61.5), anti-CD44 (IM7), anti-CD69 (H1.2F3), 
anti-CD62L (MEL-14), anti-CD45.1 (A20), anti-CD45.2 (104), anti-IFN-γ (XMG1.2), anti-
IL-4 (11B11), anti-IL-2 (JES6-5H4), and anti-Foxp3 (FJK-16s) (eBioscience), Myc (9E10, 
Santa Cruz) as well as Annexin V and 7-amino-actinomycin D (BD Biosciences) were used. 
For intracellular cytokine staining, lymphocytes were stimulated for 4 hours with 50 ng/ml 
of PMA (phorbol 12-myristate 13-acetate) and 1 μM ionomycin in the presence of brefeldin 
A. Stained cells were analyzed on an LSRII (BD Biosciences) or were sorted on a MoFlo 
(DakoCytomation; Beckman Coulter).
T cell activation, proliferation, differentiation, and Treg suppression assay
Naïve (CD62LhighCD44low) T cells were sorted from the peripheral lymph-nodes and/or 
spleens of mice. Cells were then activation by stimulation via the TCR by anti-CD3 
(145-2C11; BioXCell) and anti-CD28 (37.51; BioXCell). For proliferation assays, cells were 
labeled with CFSE (carboxyfluorescein diacetate succinimidyl ester) or CellTrace Violet 
(BD Biosciences) and then cultured under the appropriate conditions. Proliferation was 
assessed by the dilution of live dye with flow-cytometry 72–96 hours after T cell activation. 
Th1 cells were differentiated in the presence of 20ng/ml rIL-12 (R&D systems) and 20μg/ml 
anti-IL-4 (11B11, BioXcell). Th2 cells were differentiated in the presence of 20ng/ml rIL-4 
(R&D systems) and 20μg/ml anti-IFN-γ (XMG1.2, BioXcell). Treg cells were differentiated 
in the presence of 2ng/ml rTGF-β1 (R&D systems). To assess the efficacy of Treg-mediated 
immune suppression in vitro, 2x104 sorted CD4+CD25−CD45RBhi responder T cells were 
labeled with CFSE and mixed with varying amounts (as indicated) of CD4+CD25+ Treg 
suppressor cells. Cell mixtures were stimulated with soluble anti-CD3 antibody (1μg/ml) in 
the presence of 1x105 irradiated (3000 cGy) T-cell depleted splenocytes as APC. The 
proliferation of responder cells was assessed by CFSE dilution detected by flow-cytometry 
72 hours post stimulation.
Mixed–bone marrow chimeras
Bone marrow cells were isolated from the femur bones of sex- and age-matched Cd4-cre-
Tgfbr2fl/fl (CD45.2+) or Cd4-cre-Tgfbr2fl/fl-Smad4fl/fl (CD45.2+) mice and wild-type 
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(CD45.1+) mice. Bone marrow cells (1 × 106) from each donor were mixed and transferred 
into sub-lethally irradiated (400 cGy) Rag1−/− recipient mice. T cell populations of each 
donor origin were determined in the recipients 8–12 weeks after transfer.
Mouse model of the graft-versus-host response
Total splenocytes from sex- and age-matched Cd4-cre-Tgfbr2fl/fl-Smad4fl/fl (CD45.2+) or 
Cd4-cre–Smad4fl/fl (CD45.2+) mice and wild-type (CD45.1+) mice of C57BL/6 background 
were mixed at a ratio of 1:1 and then transferred into sub-lethally irradiated Rag2−/−Il2rg−/− 
mice on the BALB/c background by retro-orbital injection. Recipient mice were monitored 
and euthanized at the appropriate time. T cells from the spleens of recipient mice were 
collected and subjected to immunological analysis.
Immunoblot analysis
Protein extracts were resolved by 4–12% SDS-PAGE (Invitrogen), then were transferred to 
a polyvinylidene fluoride membrane (Millipore) and analyzed by immuno-blotting with the 
following antibodies: anti-Smad4 (#9515, Cell Signaling), anti-phospho-Smad2 (D43B4, 
Cell Signaling), anti-c-Myc (D84C12; Cell Signaling), and anti-β-actin (I-19; Santa Cruz).
ChIP assay
The ChIP assay was done according to the protocol of Upstate Biotechnology. Cells were 
crosslinked by 1% formaldehyde and were lysed in lysis buffer. Lysates were sonicated with 
a Bioruptor sonicator to shear genomic DNA into fragments. Chromatin prepared from 2 × 
106 cells were subjected to immunoprecipitation overnight at 4 °C with goat anti-Smad4 
(sc-1909; Santa Cruz) or normal goat immunoglobulin G (sc-2028; Santa Cruz). 
Quantitative real-time PCR was done to determine the relative abundance of target DNA. 
Specific primers for analysis of the binding of Smad4 to target loci are:
TBE: TGGCATATTCTCGCGTCTAGC and AGGAGTCTCTGCCGGTCTACA;
TIE: CTTTATATTCCGGGGGTCTGC and GCAATGGGCAAAGTTTCCCA;
Negative control: GGGTACATGGCGTATTGTGT and 
TCGGCTGAACTGTGTTCTTG.
Statistical analysis
Data from at least three sets of samples were used for statistical analysis. Statistical 
significance was calculated by Student’s t-test. A P value of less than 0.05 was considered 
significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Analysis of wild-type (WT), Cd4-cre-Tgfbr2fl/fl (RII KO) and Cd4-cre- Tgfbr2fl/fl-
Smad4fl/fl (RII-S4 DKO) mice
(a) The survival rate of different strains at different time after birth.
(b) Total lymphocytes recovered from the peripheral lymph-nodes (PLN), spleens and 
thymus of different strains. Means ± SD of five sets of mice are shown. (*P<0.05)
(c) CD62L and CD44 expression on peripheral T cells in different strains assessed by flow-
cytometry. Representative results of at least three experiments are shown.
(d) IFN-γ and IL-4 production in peripheral T cells in different strains assessed by flow-
cytometry. Representative results of at least three experiments (left) and means ± SD of five 
sets of mice (right) are shown. (*P<0.05)
See also Supplemental Figure 1.
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Fig. 2. Cell-intrinsic property of Tgfbr2−/−Smad4−/− T cells
(a) The percentages of T cells in the peripheral lymph-nodes (PLN), spleens and thymuses 
of mixed-bone-marrow-chimeras reconstituted with bone marrow cells from wild-type 
(CD45.1+) and Cd4-cre-Tgfbr2fl/fl-Smad4fl/fl (RII-S4 DKO, CD45.2+) mice, assessed by 
flow-cytometry.
(b) CD62L and CD44 expression on CD4+ (left) and CD8+ (right) T cells of WT and RII-S4 
DKO origins in the chimeras described in a, assessed by flow-cytometry.
(c) IFN-γ and IL-4 expression in T cells of WT and RII-S4 DKO origins in the chimeras 
described in a, assessed by flow-cytometry.
For a, b and c, representative flow-cytometry results of at least three experiments (upper 
panels) and means ± SD of five sets of mice (lower panels) are shown. (*P<0.05)
See also Supplemental Figure 2.
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Fig. 3. Defective homeostasis of Tgfbr2−/−Smad4−/− Treg cells
(a) The percentages (left) and absolute numbers (right) of Foxp3+ Treg cells detected in 
CD4+ T cells in different strains using flow-cytometry and live cell counting. Means ± SD 
of five sets of mice are shown. (*P<0.05)
(b) Immune-suppressive activity of purified WT and Cd4-cre-Tgfbr2fl/fl-Smad4fl/fl (RII-S4 
DKO) Treg cells (CD4+CD25+) assessed by in vitro suppression assay. Representative 
results (left) and means ± SD (right) of three experiments are shown.
(c) The percentages of Foxp3+ Treg cells in CD4+ T cells in the periphery of mixed-bone-
marrow-chimeras containing both wild-type (CD45.1+) and DKO (CD45.2+) T cells as in 
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Fig. 2 or of chimeras reconstituted with bone marrow cells from wild-type (CD45.1+) and 
Cd4-cre-Tgfbr2fl/fl (RII KO, CD45.2+) mice, assessed by flow-cytometry. All flow 
cytometry plots are representative of at least three experiments. All bar graphs are means ± 
SD of five mice of one experiment of two. (*P<0.05).
(d). The compositions of Treg cell populations in the Rag2−/−Il2rg−/− mice (Balb/c) that 
have received equal numbers of CD4+ T cells from wild-type mice (CD45.1+, C57BL/6) and 
DKO mice (CD45.2+, C57BL/6). Representative results of at least three experiments (left) 
and means ± SD of five recipient mice (right) in one experiment of three are shown. 
(*P<0.05)
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Fig. 4. Defective function of Tgfbr2−/−Smad4−/− T cells
(a) Anti-CD3 and anti-CD28 activated proliferation of T cells isolated from wild-type (WT) 
and Cd4-cre-Tgfbr2fl/fl-Smad4fl/fl (RII-S4 DKO) mice assessed by flow-cytometry of CFSE 
dilution (left). Division index was calculated using FlowJo software (right). Means ± SD of 
three experiments are shown. (*P<0.05)
(b) T cell sizes assessed by flow-cytometry 48 hours after anti-CD3 and anti-CD28 
stimulation.
(c) The percentages of T cells in Rag2−/−Il2rg−/− recipient mice (Balb/c) transferred with 
splenocytes from wild-type (CD45.1+) and Cd4-cre-Tgfbr2fl/fl-Smad4fl/fl (RII-S4 DKO, 
CD45.2+) mice (C57BL/6) assessed by flow-cytometry. Representative results (left) and 
means ± SD of five mice in one experiment of two (right) are shown.
(d) IFN-γ, IL-4 and Foxp3 expression in CD4+ T cells assessed by flow-cytometry after 
being differentiated under Th1, Th2 and iTreg cell polarizing conditions. Means ± SD of 
three experiments are shown.
See also Supplemental Figure 3.
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Fig. 5. Smad4 is required for T cell function
(a) The proliferation of T cells isolated from wild-type and Cd4-cre-Smad4fl/fl (S4 KO) 
mice assessed as in Fig. 4a. Means ± SD of three experiments are shown (*P<0.05).
(b) T cell sizes assessed by flow-cytometry 48 hours after anti-CD3 and anti-CD28 
stimulation. Results are representative of at least three experiments.
(c) The fractions of T cells in Rag2−/−Il2rg−/− recipient mice (Balb/c) that have received 
splenocytes from wild-type (CD45.1+) and Cd4-cre-Smad4fl/fl (S4 KO, CD45.2+) mice 
(C57BL/6) assessed by flow-cytometry. Representative flow-cytometry results (left) and 
means ± SD of five mice in one experiment representative of two (right) are shown.
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(d) CD4+ and CD8+ T cells were isolated from wild-type (CD45.1+CD45.2+) and Cd4-cre-
Smad4fl/fl mice (S4 KO, CD45.2+) mice. Cells of different origins were mixed and labeled 
with CFSE, and transferred into sub-lethally irradiated wild-type (CD45.1+) mice. The 
proliferation of transferred cells in the recipients was assessed 5 days post transfer. Results 
are representative of at least three experiments.
(e) CD4+ T cells were isolated from Cd4-cre-Smad4fl/+-OTII (WT OTII, CD45.1+CD45.2+) 
and Cd4-cre-Smad4fl/fl-OTII mice (S4 KO OTII, CD45.2+) mice, mixed at the ratio of 1 to 
1, labeled with CFSE, and then transferred into syngeneic wild-type mice (CD45.1+). The 
proliferation and the numbers of transferred cells of different origins in the spleens were 
assessed 60 hours after the recipient mice were injected with different doses of OVA 
proteins (as indicated). Representative flow-cytometry results of at least three experiments 
are shown. Means ± SD of the cell numbers are shown. (* P<0.05)
(f) The incidence of tumor development (≥3mm in diameter) in WT OTII and Cd4-cre-
Smad4fl/fl-OTII (S4 KO OTII) mice inoculated s.c. with OVA-expressing melanoma cells 
(20,000 cells/injection). Combined results of three independent experiments are plotted.
See also Supplemental Figure 4.
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Fig. 6. Smad4 controls T cell proliferation through Myc
(a and b) Myc expression in T cells assessed by flow-cytometry (left) and immuno-blotting 
(right). Representative results of at least three experiments are shown.
(c) The proliferation of wild-type and Cd4-cre-Smad4fl/fl (S4 KO) CD4+ and CD8+ T cells 
that were transduced (GFP+) with MSCV-IRES-EGFP (MIG) or MSCV-Myc-IRES-EGFP 
(MIG-Myc), assessed by flow-cytometry of CellTrace violet dilution. Results are 
representative of at least three experiments.
(d) The fractions of T cells in Rag2−/−Il2rg−/− recipient mice (Balb/c) received MIG and 
MIG-Myc transduced (GFP+) CD4+ T cells from wild-type (CD45.1+) and Cd4-cre-
Smad4fl/fl (S4 KO, CD45.2+) mice (C57BL/6) assessed by flow-cytometry. Representative 
results (left) and means ± SD of five mice in one experiment of three are shown.
(e) ChIP analysis of Smad4 binding to TGF-β-independent elements (TBE) in Myc locus in 
freshly isolated T cells. TGF-β-inhibitory elements (TIE) and an irrelevant site in Myc locus 
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was used as positive (Pos. Ctrl.) and negative (Neg. Ctrl.) controls respectively. Means ± SD 
of triplicates in one experiment of at least three are shown (*P<0.05).
See also Supplemental Figure 5.
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